Factors Influencing Clinicians' Choice of Adjuvant S-1 versus Capecitabine plus Oxaliplatin after Curative Gastrectomy in Patients with Gastric Cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Ha Yeon | - |
dc.contributor.author | Hwang, In Gyu | - |
dc.contributor.author | Park, Song-Ee | - |
dc.contributor.author | Kim, Moon Jin | - |
dc.contributor.author | Park, Se Hoon | - |
dc.contributor.author | Kang, Jung Hun | - |
dc.contributor.author | Kim, Young Saing | - |
dc.contributor.author | Oh, Sung Yong | - |
dc.contributor.author | Won, Young-Woong | - |
dc.contributor.author | Lee, Soon Il | - |
dc.contributor.author | Ji, Jun Ho | - |
dc.contributor.author | Chi, Kyong-Choun | - |
dc.date.available | 2020-02-28T06:44:34Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2016 | - |
dc.identifier.issn | 1837-9664 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/9780 | - |
dc.description.abstract | Purpose: Two recent randomized, phase III trials in Asia (ACTS-GC and CLASSIC) documented the survival benefit of postoperative chemotherapy after D2 lymph node dissection in patients with gastric cancer. We sought to determine what factors influenced clinicians' choices of either S-1 or capecitabine plus oxaliplatin (CAPOX) as adjuvant therapy after curative D2 gastrectomy. Materials and Methods: We retrospectively reviewed the clinicopathologic factors and adjuvant treatments for 435 patients from nine centers in Korea who were treated with either S-1 or CAPOX adjuvant chemotherapy after undergoing curative D2 gastrectomy between January 2013 and July 2014. Results: Of the 435 patients, 204 (46.9%) were treated with S-1 and 231 (53.1%) were treated with CAPOX. The median age at diagnosis was 61 years (range, 30-88). CAPOX was prescribed more often for patients who were 65 years of age or younger than for patients who were age 65 or older (77.1% vs. 22.9%, P<0.0001). Of the patients in stage II, 121 (60.8%) were treated with S-1 and 78 (39.2%) were given CAPOX; however, of those in stage III, 83 (35.2%) received S-1 and 153 (64.8%) were treated with CAPOX (P<0.0001). Conclusions: Clinicians only preferred CAPOX for younger patients with stage III gastric cancer after curative D2 gastrectomy. However, for elderly patients, clinicians more chose S-1 regardless of the stage. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | IVYSPRING INT PUBL | - |
dc.relation.isPartOf | JOURNAL OF CANCER | - |
dc.subject | PHASE-III TRIAL | - |
dc.subject | OPEN-LABEL | - |
dc.subject | CHEMOTHERAPY | - |
dc.title | Factors Influencing Clinicians' Choice of Adjuvant S-1 versus Capecitabine plus Oxaliplatin after Curative Gastrectomy in Patients with Gastric Cancer | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000393076400015 | - |
dc.identifier.doi | 10.7150/jca.15598 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CANCER, v.7, no.12, pp.1711 - 1715 | - |
dc.identifier.scopusid | 2-s2.0-85008462076 | - |
dc.citation.endPage | 1715 | - |
dc.citation.startPage | 1711 | - |
dc.citation.title | JOURNAL OF CANCER | - |
dc.citation.volume | 7 | - |
dc.citation.number | 12 | - |
dc.contributor.affiliatedAuthor | Kim, Young Saing | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | stomach neoplasms | - |
dc.subject.keywordAuthor | chemotherapy | - |
dc.subject.keywordAuthor | adjuvant | - |
dc.subject.keywordAuthor | gastrectomy | - |
dc.subject.keywordPlus | PHASE-III TRIAL | - |
dc.subject.keywordPlus | OPEN-LABEL | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.